The Role of the Gut Microbiome in Gastrointestinal Cancers

Cancer is a deadly malignancy of high clinical importance and remains one of the leading causes of death worldwide. Current conventional treatments for cancer include surgery, anticancer drugs, and radiation therapy. Resection surgery is the main treatment method but has a high recurrence rate. The human gut microbiome plays a crucial role in regulating various host processes, such as metabolism, inflammation, and immune and cellular responses. Moreover, it is becoming increasingly clear that the microbiome may also impact cancer development. The gut microbiota is a key component of the human microbial community, characterized by the highest number of bacteria and the greatest diversity compared to microbiomes in other parts of the body. The gastrointestinal tract (GI) extends through our natural environment, providing a suitable habitat and abundant nutrition for the microbiota. Gastrointestinal cancer encompasses a complex group of disorders and heterogeneous diseases. Both environmental and genetic risk factors can convert normal tissue into precancerous lesions, leading to the development of malignant cells. Despite advances in cancer treatment, resistance to chemotherapy and radiation therapy continues to pose a significant challenge. This is particularly relevant in light of new diagnostic and therapeutic methods for gastrointestinal tumors, which increasingly involve various strains of probiotics used as dietary supplements. As proposed treatments, probiotics may significantly benefit cancer prevention and therapy. They can enhance the metabolism of the gut microbiota during chemotherapy, potentially reducing its toxic side effects. Consequently, the potential use of probiotics as an anticancer therapy has received considerable attention in recent years. Conclusion: Current review article concentrates on the ability of probiotics to inhibit antibiotic-resistant Helicobacter pylori. However, there is a lack of studies exploring inhibitory resistance in other contexts. Despite these gaps, probiotics show considerable promise in cancer treatment and in enhancing tumor immunity.

Authors

Institutions

Publication Details

Journal
Iraqi Journal of Cancer and Medical Genetics
Published
2024-12-31
DOI
https://doi.org/10.29409/ijcmg.v17i2.378
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of the Gut Microbiome in Gastrointestinal Cancers

Mehdi Abbasnejad, Saeed Esmaeili‐Mahani, Salam Husam Sabri, Ahmed Majeed Al-Shammari et al.
Iraqi Journal of Cancer and Medical Genetics
Gut microbiota and health
article

The Role of the Gut Microbiome in Gastrointestinal Cancers

Mehdi Abbasnejad, Saeed Esmaeili‐Mahani, Salam Husam Sabri, Ahmed Majeed Al-Shammari, Khalid Jaber Kadhum Luti
article en

Abstract

Cancer is a deadly malignancy of high clinical importance and remains one of the leading causes of death worldwide. Current conventional treatments for cancer include surgery, anticancer drugs, and radiation therapy. Resection surgery is the main treatment method but has a high recurrence rate. The human gut microbiome plays a crucial role in regulating various host processes, such as metabolism, inflammation, and immune and cellular responses. Moreover, it is becoming increasingly clear that the microbiome may also impact cancer development. The gut microbiota is a key component of the human microbial community, characterized by the highest number of bacteria and the greatest diversity compared to microbiomes in other parts of the body. The gastrointestinal tract (GI) extends through our natural environment, providing a suitable habitat and abundant nutrition for the microbiota. Gastrointestinal cancer encompasses a complex group of disorders and heterogeneous diseases. Both environmental and genetic risk factors can convert normal tissue into precancerous lesions, leading to the development of malignant cells. Despite advances in cancer treatment, resistance to chemotherapy and radiation therapy continues to pose a significant challenge. This is particularly relevant in light of new diagnostic and therapeutic methods for gastrointestinal tumors, which increasingly involve various strains of probiotics used as dietary supplements. As proposed treatments, probiotics may significantly benefit cancer prevention and therapy. They can enhance the metabolism of the gut microbiota during chemotherapy, potentially reducing its toxic side effects. Consequently, the potential use of probiotics as an anticancer therapy has received considerable attention in recent years. Conclusion: Current review article concentrates on the ability of probiotics to inhibit antibiotic-resistant Helicobacter pylori. However, there is a lack of studies exploring inhibitory resistance in other contexts. Despite these gaps, probiotics show considerable promise in cancer treatment and in enhancing tumor immunity.

Iraqi Journal of Cancer and Medical GeneticsVol. 17(2)
Shahid Bahonar University of Kerman (IR), University of Baghdad (IQ), Mustansiriyah University (IQ)
Openalex Percentile: Top 77%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.